Press Releases

Date	Title
April 17, 2017	Oncobiologics Secures Additional Funding CRANBURY, N.J. , April 17, 2017 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody (mAb) biosimilar therapeutics, today announced that it has amended its
February 6, 2017	Oncobiologics Announces Term Extension of Series A Warrants CRANBURY, N.J. , Feb. 06, 2017 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (Nasdaq:ONS) (Nasdaq:ONSIW), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody biosimilar therapeutics, today announced an extension to
January 10, 2017	Oncobiologics Issues Remaining Senior Secured Notes and Warrants – Raising an Aggregate $10.0 Million CRANBURY, N.J. , Jan. 10, 2017 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today announced that it closed the sale of the remaining $1.65 million senior secured notes and warrants to purchase 379,500 shares of its common stock under its previously announced Note and Warrant Purchase
December 23, 2016	Oncobiologics Issues $8.35 Million of Senior Secured Notes and Warrants to Acquire 1.9 Million Shares as part of Aggregate $10.0 Million Note and 2.3 Million Warrant Offering CRANBURY, N.J. , Dec. 23, 2016 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody (mAb) biosimilar therapeutics, today announced that it entered into a
November 14, 2016	Oncobiologics Announces Presentation of Final Data from Phase 1 Clinical Study of ONS-3010 (HUMIRA® Biosimilar) CRANBURY, N.J. , Nov. 14, 2016 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody (mAb) biosimilar therapeutics, today presented final data from the Phase
August 31, 2016	Oncobiologics to Present at BioCentury’s NewsMakers in the Biotech Industry Conference CRANBURY, N.J. , Aug. 31, 2016 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody (mAb) biosimilar therapeutics, today announced that its Chairman, CEO and
July 6, 2016	Oncobiologics, Inc. to Present at the 2016 Cantor Fitzgerald 2nd Annual Healthcare Conference CRANBURY, N.J. , July 06, 2016 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody (mAb) biosimilar therapeutics, today announced that its Chairman, CEO and
June 16, 2016	Oncobiologics Announces First CTA Approvals for Global Phase 3 Clinical Program for ONS-3010 (Humira® biosimilar) Clinical Program Designed to Enable Interchangeability with Humira in U.S. CRANBURY, N.J. , June 16, 2016 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal
June 10, 2016	Oncobiologics Announces Separation of Units; Trading of Common Stock and Warrants CRANBURY, N.J. , June 10, 2016 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONSIU), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody biosimilar therapeutics, today announced that the 5,833,334 units
May 18, 2016	Oncobiologics Announces Closing of Initial Public Offering of Units Cranbury, NJ – May 18, 2016 — Oncobiologics, Inc. (NASDAQ: ONSIU), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics, today announced that it successfully closed its previously announced initial public